Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Patheon | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Patheon

Michael E. Lytton has been appointed Patheon’s executive vice president of Corporate Development and Strategy and general counsel.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Michael E. Lytton has been appointed Patheon’s executive vice president of Corporate Development and Strategy and general counsel. Mr. Lytton most recently served as executive vice president, Corporate and Business Development at Biogen Idec, where he reported to Jim Mullen, previously chief executive officer of Biogen Idec and now Patheon’s chief executive officer.

Mr. Lytton has 28 years of experience in the pharmaceutical and biotech industry. Most recently, he led Biogen’s corporate development team that executed its corporate partnership strategy, including the in-licensing of several late-stage molecules. Prior to joining Biogen, Mr. Lytton was a general partner with Oxford Bioscience Partners, a venture capital firm investing in therapeutic, diagnostic, and life science tool companies. Prior to Oxford, Mr. Lytton practiced law for 17 years and specialized in representing biomedical companies. Mr. Lytton is currently chairman of the board of Santhera Pharmaceuticals AG.

Mr. Mullen said, “I am so pleased that Michael has agreed to join us. He is an accomplished leader, strategist and negotiator who will bring a deep and broad understanding of the industry and proven skills to help Patheon reach its full potential. I expect that Michael will assist us in building strategic alliances with our pharmaceutical and biotechnology customers as well as emerging companies and their investors, and that he will enable us to add a range of proprietary capabilities and technologies to better serve our customers.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters